{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091801","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.804282+00:00","generated_at":"2026-05-31T12:12:03.704039+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders","bullets":["Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.","Record 213 MyoPro authorizations/orders (+70% YoY); backlog 282 units (+58% YoY).","1,179 patients in pipeline (+22% YoY); 550 new candidates added in Q2 (+35% YoY).","Gross margin 70.8% (product GM up 1,030 bps to 70.8%); net loss $1.1M ($0.03 EPS).","Q3 revenue guidance $8.0-8.5M; FY2024 revenue target $28-30M; targeting Q4 operating cash flow breakeven."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091801","json":"https://secwatch.observer/filing/0000950170-24-091801.json","markdown":"https://secwatch.observer/filing/0000950170-24-091801.md","text":"https://secwatch.observer/filing/0000950170-24-091801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024091801/0000950170-24-091801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024091801/myo-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:12:03.704039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}